Perturbations to the 1 H and 31 P chemical shifts of DNA resonances together with twenty-four intermolecular nuclear Overhauser effects show that the anthracycline antibiotic arugomycin intercalates between the basepairs of the hexamer duplex d(5'-GCATGC) 2 at the 5'-CpA and 5'-TpG binding sites. In the complex two drug molecules are bound per duplex with full retention of the dyad symmetry. Arugomycin adopts a threaded binding orientation with chains of sugars positioned in both the major and minor groove of the helix simultaneously. The complex is stabilized by hydrogen bonding, electrostatic and van der Waals interactions principally in the major groove and involving substituents on the rigidly oriented bicycloaminoglucose sugar of the antibiotic. A specific hydrogen bond is identified between the C2'-hydroxyl and the guanine N7 at the intercalation site. Together, interactions in the major groove appear to account for the intercalation specificity of arugomycin that requires both a guanine and thymine at the intercalation site. We are unable to identify any sequence specific interactions between the minor groove and the arugarose sugar (S1) which binds only weakly, through van der Waals contacts, over the d(GCA).d(TGC) trinucleotide sequence. The data indicate that the sugar chains of arugomycin are flexible and play little part in the interaction of the antibiotic with ONA. The intensity of sequential internucleotide NOEs identifies the intercalation site as being assymmetric. A family of conformers computed using restrained energy minimisation and molecular dynamics indicate that basepair buckling is a feature of the anthracycline intercalation site that may serve to maximise intermolecular van der Waals interactions by wrapping the basepairs around the antibiotic chromophore.
INTRODUCTION
The anthracycline antibiotics are active antitumour agents that bind to the DNA double helix through the process of intercalation (1) . Unique amongst this class of compounds are those, such as nogalamycin (2) (3) (4) (5) (Figure 1 ), which bear bulky sugar moieties at opposite ends of the aglycone chromophore. When threaded between the basepairs of the double helix sugars are positioned in the major and minor groove simultaneously (6-8) (see Figure 2 ). The presence of a cationic charge, which in the case of nogalamycin resides in the major groove (6) , is important in stabilising the drug-DNA complex. Arugomycin has the most complex molecular architecture of all the anthracyclines so far described (see Figure 1 ) (9) . Its DNA binding characteristics have recently been assessed by comparing its sequence recognition properties with those of nogalamycin (10) . Both drugs produce similar DNASE I cleavage inhibition ('footprinting') patterns which reveal common binding preferences for sequences containing alternating purines and pyrimidines with the dinucleotides 5'-TpG and 5'-CpA being well represented. Both antibiotics increase the susceptibility of certain adenine bases to modification by diethylpyrocarbonate illustrating their ability to alter DNA structure in a similar and sequence dependent manner (10) . The fact that both drugs share many common binding characteristics has been used as good evidence that arugomycin also behaves as a DNA intercalating agent despite the formidable mechanistic obstacle presented by its unusual molecular structure. Somewhat surprising, however, is the observation that the sugar chains of arugomycin appear to play little part in the binding interaction in that the size of the intercalation site is identical to that of nogalamycin (10) . This observation has led to the suggestion that the binding interactions are either restricted to those structural features common to both antibiotics, and that the sugar chains extend out into solution away from the DNA surface, or that they stack close to the sugar-phosphate backbone and do not impede the DNASE I cutting agent (10) . No structural data is available, from either solution or crystalline studies of an arugomycin-DNA complex, to conclusively show that this antibiotic forms a stable intercalation complex or to shed light on the roll of the sugar chains in the binding interaction. In this report we describe the structure of an (arugomycin) 2 d(GCATGC) 2 complex from the results of NMR and molecular modelling studies. Antibiotic molecules are bound at the symmetrically equivalent 5'-CpA and 5'-TpG high affinity sites previously identified (10) . A number of subtle structural differences between arugomycin and its parent compound nogalamycin present the opportunity to examine more closely the origin of the sequence selectivity exhibited by these antibiotics. In this regard we draw comparisons with our earlier data on the (nogalamycin) 2 -d(GCATGC) 2 complex (6) and with data recently reported on two crystalline nogalamycin-DNA structures (11, 12) .
MATERIALS AND METHODS Materials
Arugomycin was kindly supplied by Dr. H.Kawai of the Kirin Brewery Co. Ltd., Gunma, Japan and was used without further purification. The concentration of the (arugomycin) 2 -d(GCATGC) 2 complex was approximately 1.5 mM in 0.55 mL of buffer solution containing 50 mM NaCl and 10 mM Na 2 DPO 4 at pH 7.0.
NMR experiments 'H and
31 P NMR spectra were collected at 400 MHz on a Varian VXR400 wide-bore spectrometer and data processed, using Varian software, on a Sun 3/50 data station at the NMR Facilty of the Peter MacCallum Cancer Institute, Melbourne, Australia. Pure absorption phase-sensitive DQF-COSY, NOESY and HOHAHA spectra were acquired using the hypercomplex method of data collection (13, 14) with the carrier placed at the centre of the spectrum at the frequency of the HDO solvent resonance. The HDO resonance was suppressed, except in HOHAHA spectra, using low power selective irradiation during the relaxation period of 1 s. A spectral width of 4000 Hz was employed with 2D spectra being aquired as 1024 points (NOESY, HOHAHA) and 2048 points (DQF-COSY) in t 2 for 2x300-4001, increments, zero-filled to 1024 points in t, prior to Fourier transformation. All data sets were apodized with shifted sinebell window functions in t 2 and a mild gaussian window in NOE constraints NOE constraints for structure calculations were generated from NOESY spectra collected at 50 and 100 ms mixing times. At a mixing time of 50 ms NOEs between deoxyribose HI' and H2' are weak and represent an internal calibration distance of < 3.5A by which relative NOE cross-peak intensities can be estimated. Intermolecular NOEs that were detected at 50 ms were assigned an upper distance bound of < 3.5A and a lower bound equivalent to the van der Waals radius (2.0A). NOEs detected in the 100 ms spectrum, but which were not visible in the 50 ms spectrum, were given a larger upper distance bound of <4.5A. During the structure calculations all NOEs were assigned values of 3.5±1.5A to allow for the possible uncertainties in the experimental distance constraints. This includes any indirect effects that may be more significant in the data examined at the longer mixing time of 100 ms. We assume that the NOEs arise from a single dominant conformation, and not an averaging of . The N,N-dimethylamino group of both antibiotics is protonated at neutral pH. The carbon atom numbering is illustrated for nogalamycin but also applies to arugomycin. structures, and that the correlation times of all interproton vectors are similar. The large distance bounds imposed (2.0-5.0A) to some degree allow for possible internal dynamics. We note that the NOEs assigned upper bounds of <3.5A are generally in close agreement with calculated distances (maximum deviation +0.44A) while larger deviations are observed for a few constraints assigned upper bounds of <4.5A. Two of the 24 NOE constraints (see Table HI ) lie outside the 2.0-5.0A range (3.5±1.5A) imposed in the structural calculations.
Molecular modelling
In the absence of crystallographic data the structure of arugomycin was built from the crystal coordinates of nogalamycin (15) with the sugar arms being added using Macromodel (16) . The structure was then energy minimised, using the Tripos program Sybyl, by steepest descent and conjugate gradient calculations to yield a family of low-energy structures. Subsequent calculations were performed on a Silicon Graphics Iris 4D/220GTX computer using Insight II and Discover software from Biosym Technologies Inc. (CA, USA). The coordinates of the hexamer duplex d(GCATGC) 2 were those of idealised B-DNA and were generated using in-house software. The complex was generated by threading two randomly selected low-energy conformers of the antibiotic molecule through the DNA helix, approximately in the correct orientations, and subjecting the structure to 40,000 iterations of steepest descent energy minimisation to reduce the maximum derivative to <0.5 kJmoP'A"
1 . This process removed bad contacts between the drug molecules and DNA and pushed the basepairs apart to form an intercalation site with the correct basepair separation. Hydrogen bonding constraints within the DNA basepairs were used to maintain a double stranded structure. After the introduction of the 24 NOE constraints the structure was subjected to restrained energy minimisation for a further 500 iterations at 300K. Solvent and counterions were not explicitly included in the calculations but were simulated through the use of a distance dependent dielectric of one times the radius. Amber force fields were used throughout. The NOE effective potential term was scaled by a factor of 10 during calculations and 1,4 electrostatic interactions damped by a scaling factor of 
was repeated 38 times to give an overall search of conformational space equivalent to 152 picoseconds. All quenched structures had an RMS gradient of <0.1 kJmor'A . The chain of interactions is traced between base H6/H8 (6.6 -8.3 ppm) and the H2" (1.7-3.0 ppm) of the 5'-flanking sugar. The internucleotide interactions at the 4T-5G step are similarly disrupted and those at the 2C-3A step are weak compared with the interactions at the 5'-pur-pyr-3' steps where no antibiotics are bound. The integrity of the stacking interactions between 3A and 4T is confirmed by a strong NOE between 3AH8 and 4T-CH 3 . The 3AH2 resonance cannot be assigned as part of any sequential pathway but is identified on the basis of an intense NOE from the 4TH1 resonance identified at 12.90 ppm in H 2 O solution (data not shown). The relative intensity of the intranucleotide NOEs (H6/H8-H2'>H6/H8-H1"~H6/H8-H3' and H1'-H2">H1'-H2') observed in 50 ms NOESY spectra (data not shown) are consistent with sugar geometries lying broadly within the C2'-endo region of conformational space while the glycosidic bond angles fall in the anti range, characteristic of the B-DNA conformation. The chemical shift values for d(GCATGC) 2 in the complex are presented in Table I . The ! H complexation shifts observed for the oligonucleotide H1/H3, HI', H6/H8 and H2/H5/CH 3 resonances are plotted against sequence position in Figure 5 for the binding of both nogalamycin and arugomycin to d(GCATGC) 2 . The sequencedependent pattern of complexation shifts observed for arugomycin are generally very similar to those for nogalamycin which strongly supports the notion that both antibiotics intercalate at the same 5'-CpA and 5'-TpG dinucleotide sites and both stack in a similar manner with the DNA basepairs.
RESULTS AND DISCUSSION

DNA resonance assignments and complexation shifts
Arugomycin resonance assignments
The complexity of the ! H spectrum of the (arugomycin) 2 -d(GCATGC) 2 complex precludes a complete sequence-specific assignment of all sugar moieties of the bound antibiotic at 400 MHz. However, many resonance assignments from the aglycone chromophore and within sugar ring A, the arugarose sugar SI, the bicycloaminoglucose sugar and the sugars of the attached chain S5-S6-S7 are presented here and permit a large number 4TCH, E a. 
of intermolecular interactions to be identified and many specific features of the complex to be established. Assignment of all but the H57H5" nucleotide resonances is particularly helpfull in this regard.
A set of sequential NOEs starting with the aromatic 11-H of aglycone ring B and extending into sugar ring A are readily identified in the NOESY spectrum. Correlations are detected between 11-H (6.66 ppm) and 10-H (4.09 ppm) which in turn both give cross-peaks to 9-Me (1.42 ppm). 9-Me, 10-H and 11-H all give weak NOEs to a methoxy resonance at (3.81 ppm) which we readily identify as 10-OMe. 9-Me also has strong interactions to a pair of geminal protons, not previously identified as deoxyribose H27H2", which can be assigned to 8-H (1) and 8-H C) at 1.89 and 2.87 ppm. Both COSY and NOESY spectra extend the assignments from 8-H to 7-H at 4.64 ppm (see Figure 6 ). An intense NOE (<2.5A) from 7-H to 1"-H, at 5.26 ppm, and weaker effects from 8-H to 1"-H connects sugar ring A to the arugarose sugar (SI). COSY and NOESY correlations identify 2"-H and 3"-H on this sugar while weak NOE crosspeaks from 1 "-H and 9-Me to a methoxy resonance at 3.35 ppm identifies the latter as 3"-0Me. Poor resolution and the associated ambiguities prevent the spin-system of SI from being fully assigned.
Resonance assignments within the bicycloaminoglucose sugar are initiated by an NOE from the aromatic proton 3-H at 6.89 ppm to 5'-Me at 1.61 ppm. NOE cross-peaks from 3-H and 5'-Me to a resonance at 4.39 ppm readily extends the assignments to 4'-H. From 4'-H a large intense NOE is observed to a single broadened methyl resonance at 3.00 ppm which we attribute to the 3'-NMe2 group. The observation of only a single, but intense, NOE from the 3'-NMe2 group to a proton or protons centred around 4.39 ppm leads us to conclude that 4'-H, 3'-H and 2'-H have closely similar chemical shift values. This notion is in part confirmed by the observation of a COSY/HOHAHA crosspeak from 4.39 ppm to l'-H at 5.67 ppm which indicates that 2'-H does lie under this group of resonances. Proton assignments are readily extended to the 2-deoxy-L-fucose sugar (S5) on the basis of their close proximity to the protons of the bicycloamino sugar (see Figure 6 ). For example, 3-H, 4'-H and 5'-Me all give very intense NOEs to an anomeric sugar proton at 5.36 ppm which is readily assigned to 1"-H (S5). 4'-H and 5'-Me are close in space to 2"-H (1.99 and 2.07 ppm) while a weak interaction is observed between 1"-H and 3'-NMe2. 3"-H (55) is identified at 4.13 ppm through scalar coupling interactions to 2"-H. 5"-H and 5"-Me on S5 are mutually scalar coupled and both give NOE cross-peaks to 3"-H (S5) and to 3'-NMe2 and 4'-H on the bicycloamino sugar. Sequential NOEs from 5"-H and 5"-Me of S5 identify the 1"-H of the L-decilonitrose sugar S6, at 5.29 ppm. Scalar coupling interactions identify the 2"-H (56) geminal protons at 1.95 and 2.68 ppm whose large chemical shift separation presumably arises from the anisotropic environment surrounding the 3"-NO 2 group. Both 2"-H of S6 give NOEs to 5"-H and 5"-Me of S5. The 3"-Me (S6) is identified at 1.67 ppm on the basis of NOEs to both 1"-H and 2"-H of S6. Weak NOEs from 2"-H identify 4"-H (S6) at 3.75 ppm. This assignment is confirmed by a strong NOE from 3"-Me (S6) to 4"-H (S6) and a weaker effect from a methyl doublet at 1.16 ppm which we assign to 5"-Me (S6), coupled to 5"-H (S6) at 3.96 ppm. 5"-H (S6) also gives a weak NOE to 4"-H (56) as does 3"-Me (S6) to 5"-Me (S6). The spin-system of S7 is assigned by a strong sequential NOE from 4"-H (S6) to 1 "-H (57) at 5.09 ppm which is complimented by a weaker effect from 3"-Me (S6) to 1 "-H (S7). COSY correlations enable us to extend S7 assignments to the 2"-H and 3"-H but no further. Arugomycin chemical shift assignments are presented in Table II . 
Intermolecular interactions
Many intermolecular interactions between arugomycin and d(GCATGC) 2 define more clearly the position and orientation of the antibiotic molecules in the complex. These interactions are summarized in Table HI with many of the relevant NOE crosspeaks being explicitly highlighted in the various NOESY figures. In Figure 3B intermolecular interactions are identified between the deoxyribose HI', which provide markers in the minor groove, and methyl and methoxy groups on the bound antibiotic. The data reveal that ring A and the arugarose sugar (SI) lie in the minor groove and many intermolecular contacts are observed between the two. For example, on sugar ring A NOEs are identified from 9-Me to the deoxyribose HI' and H4' of both 5G and 6C, from 10-OMe to 4TH1' and 3AH2, and from 10-H to HI' and H4' of 5G. The aromatic 11-H on ring B of the aglycone chromophore is directed towards the deoxyribose rings of 4T and 5G and is close to 4TH1', 4TH272" and 5GH1', 5GH272", 5GH 3 ' and 5GH4'. The data are consistent with the aglycone ring B being displaced towards the minor groove side of the helix with it and sugar ring A protruding into the groove, as illustrated for one low-energy structure in Figure 7 . The arugarose sugar (SI) interacts only weakly with the minor groove forming NOE contact points between 1"-H (SI) and 3AH1', and between 3"-0Me and 6CH1'. This latter NOE marks the limit of the binding interaction and indicates that the arugarose sugar (SI) occupies the minor groove over the span of three basepairs 5'-GCA (5'-TGC). Intermolecular NOEs are also observed from marker protons in the major groove, for example, from 4TCH3 to arugomycin l'-H and 5'-Me and from 2CH5 to 3-H which clearly positions the bicycloaminoglucose sugar in the wider groove and identifies a number of non-polar interactions with the edges of the basepairs. There is generally very good agreement between the experimental intermolecular NOE data and the results of molecular modelling studies. The experimental and calculated interproton distances for one of the family of lowenergy structures generated (see Figure 7 ) are presented in Table  HI for comparison.
Stabilisation of the complex and binding specificity
The molecular modelling studies, represented by the structure depicted in Figure 7 , reveal that stabilisation of the complex through electrostatic and hydrogen bonding effects involves interactions with the trinucleotide sequence 5'-GCA (5'-TGC) principally in the major groove. The 2'-hydroxyl of arugomycin is oriented by the rigid bicyclic sugar and is in a position to form a direct hydrogen bond (1.8A) to the N7 of the guanine base at the (C-G).(A-T) intercalation site. This interaction offers some explanation for the sequence specificity that requires a guanine base at this position. The protonated dimethylamino group is also positioned in the major groove close to the guanine O67N7 of the terminal basepair where the possibility of electrostatic interactions and water mediated hydrogen bonds are capable of stabilizing the complex. These interactions are also apparent when nogalamycin binds at the same site (6) and have recently been identified at the 5'-CpG intercalation sites in recent crystal structures of two (nogalamycin)2-d(CGTpSACG)2 complexes (where pS is thiophosphonate) reported by different groups (11, 12) . The role of the 4'-hydroxyl of nogalamycin in these two structures is, however, different. In one no direct hydrogen bond is formed with the G-C basepair (11) while in the other structure the 4'-hydroxyl receives a hydrogen bond from the cytosine amino group (12) . The structural modification at the C4' position of arugomycin precludes any such interaction in its DNA complex which highlights the 2'-hydroxyl/DNA interaction as having evolved as a primary determinant of specificity in this family of anthracyclines.
In the crystal structures of nogalamycin bound to the 5'-CpG site the carbonyl oxygen of the methyl ester group at C-10 hydrogen bonds to the 2-amino group of guanine. Some importance has been attached to this interaction from which it was concluded that the binding preferences of nogalamycin are for G-C basepairs immediately surrounding the intercalation site (11) . Such an interaction is precluded in our complexes where the guanine base is replaced with an adenine, which lacks the 2-amino group, and yet many 5'-CpA and 5'-TpG binding sites are strongly protected in footprinting studies with natural DNA (10) . There appear to be no direct opportunities for complex stabilising hydrogen bonds between arugomycin and the minor groove when bound to the 5'-CpA and 5'-TpG sites. The 9-hydroxyl group points out into solution and not towards the floor of the groove. There are, however, a number of van der Waals interactions with the walls of the minor groove which may contribute to the binding energy but do not appear to impart any degree of sequence selectivity to arugomycin. These intermolecular contacts involve a hydrophobic patch of substituents on ring A which extend from 9-Me to 10-H, 10-OMe and to 11-H on aglycone ring B. All are in close proximity to the deoxyribose protons of nucleotides along the 5'-TGC portion of the sequence. The arugarose sugar (SI), in contrast to the nogalose of nogalamycin, interacts only weakly with the minor groove through van der Waals contacts with 1"-H and 3"-OMe. The nogalose ring has five methyl/methoxy groups compared with the two found for the equivalent sugar ring of arugomycin. Consequently, a larger number of drug-DNA contacts are apparent in the minor groove (6) than are observed for the arugarose sugar of arugomycin. On the nogalose ring a number of these substituents are arranged in a hydrophobic cluster close to the walls and floor of the minor groove. Both antibiotics utilise the hydrophobic bridgehead atoms, l"-H~O-5"-Me of the bicyclo sugar, to establish van der Waals interactions with the thymine methyl group in the major groove (see Figure 7A) , an interaction capable of contributing significantly to the binding energy (19) . Here we identify the possible role of the thymine base in the intercalation site specificity.
Distortions of the DNA structure Drug chromophores are intercalated at the 5'-CpA and 5'-TpG steps in the complex with d(GCATGC) 2 and disrupt the stacking interactions between the G-C and A-T basepairs. While the internucleotide 2CH1'-3AH8 sequential NOE is readily detected, although less intense than found in the ligand-free duplex, the NOE between 4TH1' and 5GH8 is completely absent (>5.0A) from the 250 ms NOESY spectrum (see Figure 3A) . These observations are consistent with an assymmetry of the drug binding site which the modelling studies suggest can be incorporated into a partially unwound DNA structure in which the basepairs immediately surrounding the antibiotic are appreciably buckled. The resulting structures from molecular dynamics calculations on the arugomycin complex with d(GCATGC) 2 reveal that while the 4T and 5G bases are essentially parallel the 2C and 3A bases are oriented in a wedgeshaped alignment. The binding site geometry, in the absence of the bound drug molecule, is illustrated in Figure 8 for one of the d(GCA).d(TGC) intercalation sites. The drug chromophore stacks principally on the six membered ring of the guanine base to the 5'-TpG side of the intercalation site as illustrated in Figure 7A . This orientation is totally consistent with the large ring-current perturbations that are observed to the chemical shifts of 3AH2 and 4TH3 which are positioned directly above the drug chromophore as is also clearly evident in Figure 7A . The notion that the basepairs wrap around the drug molecules and so maximise van der Waals interactions between the two, as is apparent in these structures, has found support from recent nogalamycin-DNA crystal structures where basepair buckling of up to 26° has been identified (11, 12) . Similar distortions, but on a smaller scale (16°) have also been observed for daunomycin (20) and may be a common feature of anthracycline-DNA complexes. In the present study changes in 31 P chemical shifts provide some estimate of the extent to which the sugar-phosphate backbone of the DNA is perturbed upon ligand binding and have previously been proposed to be directly correlated with helix unwinding (21) (22) (23) . The data in Figure 9 illustrate that much larger assymmetric perturbations are associated with nogalamycin binding indicating, at least qualitatively, that there are differences in phosphodiester torsion angles in the backbone of these two complexes. The nogalamycin 3I P chemical shift data are consistent with the binding site assymmetry identified in one of the (nogalamycin) 2 -d(CGTACG) 2 crystal structures (12) where one of the two phosphodiester groups at each of the intercalation sites is appreciably unwound with a helical twist angle of only 25° compared with 36° in B-DNA. In contrast, the helical twist angles at the 5'-CpG intercalation sites in the other crystal structure (11) are 37°, indicative of a small overwinding. The remaining basepair steps have a combined unwinding angle of -11°, reminiscent of that observed for daunomycin complexes with the same hexamer duplex (20) . The relatively small perturbations to the P chemical shifts in the (arugomycin) 2 -d(GCATGC) 2 complex suggest that unwinding is spread over a number of basepairs in small increments (daunomycin-like) rather than at a single site as observed in one nogalamycin-DNA crystal structure (12) . In this regard the conformation of the arugomycin and nogalamycin complexes with d(GCATGC) 2 appear to be quite different. Our calculated structures of the arugomycin/DNA complex indeed suggest that unwinding of the helix at the intercalation site is negligible, however, we are not confident that the quality of our computed structures is sufficiently high at this stage of refinement to be able to distinguish unambiguously between these two models of helix unwinding.
Orientation of the sugar chains of arugomycin
The NOE data and structural calculations enable us to throw some light on the role of the sugar chains of arugomycin in the binding interaction. The orientation of S5 in the major groove is defined by intermolecular NOEs from the anomeric 1 "-H and geminal 2"-H of S5 to 3-H, 4'-H and 5'-Me on the adjacent bicycloaminoglucose sugar and aglycone ring D of the chromophore. S5 and the rest of the sugar chain is oriented away from the major groove (see Figure 7) on the solvent-exposed face of the bicyclo sugar. This orientation is consistent with the absence of NOEs from protons of S5 to any protons associated with the major groove. In the minor groove an intense NOE between 7-H and 1"-H (SI) (<2.5A) and weaker effects from 1"-H to 8-H orients ring A and the arugarose sugar in a conformation similar to that found for the nogalose in the crystal structures of both free and DNA-bound nogalamycin (11, 12, 15) were the torsion angles C8-C7-O7-C1" and C7-O7-C1 "-C2" have values of ~ 100° and ~ 160°, respectively. Thus, the arugarose sugar (SI) would appear to occupy the same orientation and the same region of conformational space within the minor groove as does the nogalose of nogalamycin. This is consistent with both the methoxy group of the arugarose sugar, and its nogalose equivalent 3"-0Me, giving a strong NOE to the deoxyribose HI' of 6C (see Figure 3B ). The sugar rings S2, S3 and S4 in the complex extend beyond the ends of this short duplex, and are not presented with the opportunity to bind to the minor groove. The unrestrained sugar chain in our family of low-energy structures adopts a large number of different conformations but orientations are favoured which tend to bend the sugar chain away from the DNA surface out into solution (see Figure 7) . Consequently it seems unlikely that the S2-S3-S4 chain would interact with the minor groove in a longer sequence of DNA.
Overview of the arugomycin-DNA structure Arugomycin intercalates between the basepairs of DNA and forms a stable complex despite the presence of long sugar chains at either end of the chromophore which must present a formidable mechanistic obstacle to the binding process. This class of anthracyclines has evolved with a rigid bicycloamino sugar that very effectively orients different functional groups towards hydrogen bond acceptors on the edges of the basepairs in the major groove. Many interactions between the drug and DNA that appear to contribute to the sequence specificity of this class of antibiotics for the 5'-CpA (5'-TpG) site stem from functional groups on this sugar oriented in the major groove. Arugomycin and nogalamycin are unique in this respect in that many antibiotics have evolved to attack the minor groove where few proteins bind specifically (24) .
Mechanisms of binding of such complex anthracyclines require considerable conformational flexibility on the part of the DNA molecule, with cooperative local melting of several base pairs being forwarded as one possibility. An alternative mechanism has been suggested for the binding of nogalamycin to natural DNA (12) and involves an unstacked, fully extended helical structure, in which the paired bases at the intercalation site are buckled. This mechanism does not appear to pose a severe steric block to certain conformations of nogalamycin (12) and, by analogy, must also be a possible mode of binding for arugomycin.
The sugar chains of arugomycin play little part in the binding interaction with DNA and are directed out into solution.
Interactions that stabilise the complex are restricted to structural features common to both arugomycin and nogalamycin. Our structural data correlate with the footprinting results which identify a binding site size for arugomycin which is identical to that of nogalamycin which lacks the sugar chains. Further evidence of a passive role for these bulky residues is shown by the fact that deleting these sugar chains, in part or fully, does not abolish the antitumour activity (25) . Indeed, the biological data on their relative antitumour activity and cytotoxicity suggests that arugomycin and nogalamycin are of similar potency (8) . It is known that the anthracycline antibiotics display a wide range of biological activities and properties not entirely dependent on their ability to bind to DNA. Some evidence exists to suggest that they interfere with topoisomerase II by stabilising a 'deadend' drug-enzyme-DNA cleavage complex (26, 27 ). An analysis of the cytotoxicity exhibited by the anthracyclines must, therefore, take into consideration their ability to interact with proteins where the sugar chains of the antibiotic might take on a different role in the molecular recognition process.
